Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2015-02-10 Investor Presentation
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
February 2015 Newsletter 6 pages 1.1MB
Investor Presentation Classification · 90% confidence The document is a detailed company update from February 2015, containing messages from the CEO, research updates, patent grants, and business development news. It includes extensive narrative on product development, intellectual property, research collaborations, and sales growth. There are no financial statements, quarterly or annual financial results, or regulatory form references such as 10-K or 10-Q. The content is more akin to a corporate newsletter or investor update rather than a formal financial report or regulatory filing. It does not fit the categories of Annual Report, Interim Report, Earnings Release, or Audit Report. It also does not announce voting results, capital changes, or management changes. Given the nature of the content—company progress, research, patents, and business updates—it best fits the category of an Investor Presentation (IP), which often includes strategic, operational, and market position information for investors. The document length and detail support this classification with high confidence.
2015-02-10 English
Appendix 4C - quarterly 6 pages 290.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'NOTES TO APPENDIX 4C' and includes the Appendix 4C form, which is a quarterly report for entities admitted on the basis of commitments. It contains detailed financial data such as cash flows from operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The document covers the quarter ended 31 December 2014 and provides substantive financial information and analysis for that period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not merely an announcement or a certification but includes detailed financial statements and notes. Therefore, the correct classification is IR with high confidence. Q2 2015
2015-01-27 English
USA Patent Granted for Treatment of Heart Failure 2 pages 92.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the granting of a USA patent for the use of midkine to treat heart failure. It discusses intellectual property, patent coverage, and the company's patent portfolio. There is no financial data, no mention of financial results, no regulatory certifications, no voting results, no management changes, no earnings information, and no report publication statements. The content is focused on a patent grant announcement, which is a regulatory announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report itself but an announcement of a patent grant. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2015-01-20 English
Australian Patent Granted for Use of Midkine for Hair Growth 2 pages 95.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the granting of a patent related to the use of midkine for hair growth. It discusses intellectual property, patent protection, and business strategy related to the patent. There is no financial data, no mention of financial results, no regulatory filings, no management changes, no voting results, no earnings information, and no report publication. The content is clearly an announcement of a patent grant, which is a regulatory announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. The best fitting category is Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2015-01-11 English
Cleansing Notice and Appendix 3B 13 pages 207.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Cleansing Statement - Notice under section 708A(5)(e) of the Corporations Act' and includes an Appendix 3B form, which is a 'New issue announcement, application for quotation of additional securities and agreement.' The content details the issuance of fully paid ordinary shares, the number of securities issued, issue price, purpose of the issue, and compliance with relevant Corporations Act provisions. It is a regulatory announcement related to capital raising and securities issuance rather than a financial report or earnings release. The document is lengthy (15,000 characters) and contains detailed information about the securities issued and compliance statements, typical of a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-12-17 English
Cellmid Capital Raising 1 page 76.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'CELLMID CAPITAL RAISING' dated 15 December 2014. It details the receipt of commitments totaling approximately $1.3 million for new fully paid shares issued at a discount, describing the placement terms, investor types, and intended use of funds. There is no financial statement or detailed financial analysis included, only an update on a financing activity. The document length is 2855 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the definition of a Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or Earnings Release. Therefore, the correct classification is CAP with high confidence.
2014-12-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.